Table 4 HyperK – baseline characteristics
Derivation n = 754,109 | Validation n = 323,197 | |
|---|---|---|
Mean age (years) | 43.1 ± 18.4 | 43.0 ± 18.4 |
< 65 years | 85.1% | 85.2% |
65–74 years | 8.4% | 8.3% |
≥ 75 years | 6.5% | 6.5% |
Sex (male)* | 41.7% | 41.5% |
Hypertension | 21.5% | 21.4% |
Hyperlipidaemia | 18.0% | 17.9% |
Diabetes | 7.4% | 7.3% |
Smoking | 13.0% | 12.9% |
ASCVD | 4.2% | 4.1% |
Heart failure | 2.6% | 2.6% |
Atrial fibrillation | 2.5% | 2.5% |
Renal failure | 1.5% | 1.5% |
Dialysis* | 0.2% | 0.2% |
ACEi | 5.6% | 5.6% |
ARB | 2.2% | 2.2% |
Beta-blocker | 4.5% | 4.5% |
Aldosterone | 0.6% | 0.6% |
NSAID | 25.3% | 25.3% |
Furosemide | 2.2% | 2.3% |
Torsemide | 0.1% | 0.1% |